Rennova Health's Pharmacogenomics Subsidiary Granted Patent

Rennova Health, Inc. ( NASDAQ: RNVA), (NASDAQ: RNVAZ) (“Rennova” or the “Company”), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, announced today that its Genomas, Inc. pharmacogenomics subsidiary has been granted a Patent by the US Patent and Trademark Office.
Genomas is a biomedical company bringing DNA-Guided medicine to clinical practice with products for the personalized prescription of drugs used in the treatment of mental illness, diabetes and cardiovascular disease (CVD). Its products eliminate trial-and-error prescription with DNA-Guided medicine and enable physicians to treat with unprecedented precision, avoiding significant drug side effects, improving efficacy and enhancing patient compliance.
The US Patent and Trademark Office has recognized that a combinatorial genotype is an invention, having dimensions that exceed single gene testing. The PTO has granted a patent for the combination of CYP2C9 + CYP2C19 + CYP2D6. These are the three fundamental but genetically variable routes of drug metabolism for most of the neuropsychiatric and cardio metabolic medicines in healthcare.
Dr. Gualberto Ruaño, lead inventor of the patent, stated: “In this patent, we describe a combinatorial approach to CYP2C9, CYP2C19 and CYP2D6 genotyping as a physiological ensemble or PhyzioType. We believe this combinatorial approach represents an improvement over the current gene-by-gene method by providing greater scope while still allowing for the resolution of a single gene index. This will result in novel clinical and research applications facilitating the translation of pharmacogenomics research to personalized medicine, particularly in psychiatry and pain management where many drugs depend on multiple CYP450 pathways.”
A PhyzioType System consists of three components: an array of inherited, stable DNA polymorphisms from various genes to establish a patient’s combinatorial genotype; bio-clinical algorithms for predicting the patient’s drug response; and a portal for doctors to select the best drug for the patient. PhyzioType Systems can be employed prognostically before prescribing drugs or diagnostically to manage patients evidencing drug intolerance or resistance.
“This is an exciting development for Rennova and is evidence of our effort to be a leading and innovative provider of healthcare solutions.” said Seamus Lagan, Rennova CEO. “In addition to our own efforts to capitalize on this patented technology in the personalized medicine industry by including these three key genes in diagnostic panels, we will explore business partnerships and licensing opportunities.”
About Rennova Health, Inc.
Rennova provides industry-leading diagnostics and supportive software solutions to healthcare providers, delivering an efficient, effective patient experience and superior clinical outcomes. Through an ever-expanding group of strategic brands that work in unison to empower customers, we are creating the next generation of healthcare. For more information, please visit www.rennovahealth.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Additional information concerning these and other risk factors are contained in the Company’s most recent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.